Regenerative Medical Technology Group Inc. (RMTG) develops next-generation regenerative medicine therapies targeting complex disease states with a growing revenue base.
RMTG demonstrates strong top-line growth with revenue tripling over the last three years, signaling successful market penetration for its regenerative products. The positive operating cash flow in 2024 suggests an improving operational efficiency that could precede a return to profitability once R&D and SG&A costs stabilize. Investors may see value in the company's niche focus on regenerative medicine, a high-growth sector with substantial unmet medical needs.
The company faces severe financial distress with total liabilities exceeding assets by nearly $27M, resulting in negative shareholders' equity and retained earnings deficit. Consistent net losses over the past five years indicate that current revenue levels are inadequate to cover operating costs and sustain the business long-term. The OTC listing combined with a lack of major institutional support and high debt obligations presents substantial downside risk for capital preservation.
Regenerative Medical Technology Group Inc. is a biotechnology and medical technology company focused on developing innovative regenerative medicine solutions to treat complex conditions. The company serves the global healthcare market with a portfolio of products aimed at accelerating tissue repair and regeneration. Key revenue streams include product sales, licensing agreements, and potentially clinical trial support services typical for early-stage med-tech firms.
Despite a 174% revenue increase from $1.5M in 2022 to $4.1M in 2024, the company continues to report significant losses, with net income remaining negative at -$5.6M. Operating expenses of $2.7M alongside cost of revenue at $1.3M suggest the business is scaling sales while managing high burn rates. The cash flow from operations turned positive at $850k, a notable improvement over the previous years' losses, yet it is insufficient to offset capital expenditures and other investing outflows.
The regenerative medicine industry is experiencing rapid expansion driven by advancements in stem cell technology and tissue engineering to treat chronic and degenerative diseases. This sector attracts significant venture capital but remains highly competitive, requiring substantial R&D investment and regulatory approval before products can generate sustained revenue. Companies must navigate complex FDA pathways while managing long development timelines and high clinical trial failure rates.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $1.5M | $2.4M | $4.1M |
| Cost of Revenue | $653.3K | $734.3K | $1.3M |
| Gross Profit | $877.0K | $1.7M | $2.8M |
| Operating Expenses | $2.1M | $2.4M | $2.7M |
| Operating Income | $-1.2M | $-715.2K | $81.2K |
| G&A | $424.3K | $752.5K | $798.3K |
| D&A | $152.7K | $310.1K | $220.6K |
| Depreciation | $152.7K | $212.6K | $123.0K |
| Amortization | — | — | $97.5K |
| Other OpEx | $1.6M | $1.6M | $1.9M |
| Non-Operating Income | $-5.5M | $-11.2M | $0 |
| Pre-Tax Income | $-6.7M | $-11.9M | $81.2K |
| Income Tax | $-1.2M | $-2.1M | $-1.2M |
| Continuing Ops | $-5.6M | $-9.8M | $1.2M |
| Discontinued Ops | $68.3K | $0 | $0 |
| Net Income | $-5.5M | $-9.8M | $-5.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-5.5M | $-9.8M | $-5.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $1.7M | $575.0K | $1.2M |
| Cash & Equivalents | — | $530.5K | — |
| Inventory | — | — | $10.1K |
| Other Current Assets | — | $44.5K | $1.2M |
| Long-Term Assets | $6.4M | $2.3M | $2.6M |
| PP&E (Net) | $186.3K | $359.3K | $451.7K |
| Intangibles | $354.1K | $256.5K | $159.0K |
| Goodwill | $5.8M | $1.7M | $1.7M |
| Operating Leases | $34.0K | $2.7K | $275.3K |
| Other LT Assets | $5.6K | $5.6K | $7.3K |
| Total Assets | $8.1M | $2.9M | $3.8M |
| Current Liabilities | $12.0M | $22.2M | $29.0M |
| Accounts Payable | $245.5K | $421.3K | $1.3M |
| Current Leases | $32.6K | $2.7K | $63.5K |
| Deferred Revenue | — | — | $55.7K |
| Other Current Liab | $7.1M | $15.2M | $17.8M |
| Long-Term Liabilities | $8.1M | $2.4M | $2.2M |
| LT Operating Leases | $1.4K | — | $211.7K |
| Other LT Liab | $8.1M | — | $2.0M |
| Total Liabilities | $20.1M | $24.7M | $31.2M |
| Shareholders' Equity | $-12.0M | $-21.8M | $-27.4M |
| Paid-In Capital | $40.2M | $40.2M | $40.2M |
| Retained Earnings | $-52.2M | $-62.0M | $-67.6M |
| Total L&E | $8.1M | $2.9M | $3.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-5.5M | $-9.8M | $-5.6M |
| Non-Cash Adjustments | $1.8M | $6.0M | $2.3M |
| Working Capital Changes | $2.6M | $3.4M | $4.1M |
| Cash from Operations | $-1.1M | $-419.2K | $850.7K |
| Capital Expenditures | $198.4K | $385.6K | $215.4K |
| Cash from Investing | $-198.4K | $-385.6K | $-215.4K |
| Cash from Financing | $-20.8K | $-309.9K | $0 |
| FX Effect | $0 | $1 | $0 |
| Net Change in Cash | $-1.3M | $-1.1M | $635.3K |
| Beginning Cash | $3.0M | $1.6M | $530.5K |
| Ending Cash | $1.6M | $530.5K | $1.2M |
Product Sales of Regenerative Therapies: Core revenue driver from commercializing proprietary medical devices or biologics. Licensing and Collaboration Revenue: Income generated from partnering with larger pharmaceutical or device companies for technology rights. Clinical Operations: Potential revenue from conducting pre-clinical or clinical trials, though currently a net cost center based on cash flow data.
Significant Negative Net Income: The company posted a $5.6M loss in 2024, indicating cash burn that must be addressed before profitability. High Debt and Liability Structure: Total liabilities of $31.2M against only $3.8M in assets creates a precarious solvency position with negative equity. Limited Cash Reserves: Ending cash of $1.2M may not sustain operations long-term without additional financing or revenue acceleration. OTC Market Volatility: Trading on the OTC market exposes investors to lower liquidity and higher price volatility compared to major exchanges.
Proprietary IP Portfolio: Exclusive rights to regenerative technologies that create high barriers to entry against competitors. Strategic Licensing Partnerships: Ability to monetize technology through alliances with established industry players without heavy capital outlay for manufacturing. Niche Market Focus: Specialization in underserved therapeutic areas where large competitors lack dedicated pipelines.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.